Diabetes Complications Division, Baker IDI Heart & Diabetes Research Institute, PO Box 6492, St Kilda Rd, Melbourne, VIC, 8008, Australia,
J Mol Med (Berl). 2014 May;92(5):441-52. doi: 10.1007/s00109-014-1146-1. Epub 2014 Apr 1.
With the increasing incidence of obesity and type 2 diabetes, it is predicted that more than half of Americans will have diabetes or pre-diabetes by 2020. Diabetic patients develop vascular complications at a much faster rate in comparison to non-diabetic individuals, and cardiovascular risk is increased up to tenfold. With the increasing incidence of diabetes across the world, the development of vascular complications will become an increasing medical burden. Diabetic vascular complications affect the micro- and macro-vasculature leading to kidney disease often requiring dialysis and transplantation or cardiovascular disease increasing the risk for myocardial infarction, stroke and amputations as well as leading to premature mortality. It has been suggested that many complex pathways contribute to the pathobiology of diabetic complications including hyperglycaemia itself, the production of advanced glycation end products (AGEs) and interaction with the receptors for AGEs such as the receptor for advanced glycation end products (RAGE), as well as the activation of vasoactive systems such as the renin-angiotensin aldosterone system (RAAS) and the endothelin system. More recently, it has been hypothesised that reactive oxygen species derived from NAD(P)H oxidases (Nox) may represent a common downstream mediator of vascular injury in diabetes. Current standard treatment of care includes the optimization of blood glucose and blood pressure usually including inhibitors of the renin-angiotensin system. Although these interventions are able to delay progression, they fail to prevent the development of complications. Thus, there is an urgent medical need to identify novel targets in diabetic vascular complications which may include the blockade of Nox-derived ROS formation, as well as blockade of AGE formation and inhibitors of RAGE activation. These strategies may provide superior protection against the deleterious effects of diabetes on the vasculature.
随着肥胖症和 2 型糖尿病发病率的不断上升,预计到 2020 年,将有超过一半的美国人患有糖尿病或糖尿病前期。与非糖尿病患者相比,糖尿病患者的血管并发症发展速度要快得多,心血管风险增加了十倍以上。随着全世界糖尿病发病率的不断上升,血管并发症的发展将成为一个日益沉重的医疗负担。糖尿病血管并发症影响微血管和大血管,导致肾脏疾病,通常需要透析和移植,或心血管疾病,增加心肌梗死、中风和截肢的风险,并导致过早死亡。有人认为,许多复杂的途径导致糖尿病并发症的病理生物学,包括高血糖本身、晚期糖基化终产物(AGEs)的产生以及与 AGEs 受体如晚期糖基化终产物受体(RAGE)的相互作用,以及血管活性系统如肾素-血管紧张素醛固酮系统(RAAS)和内皮素系统的激活。最近,有人假设来自烟酰胺腺嘌呤二核苷酸磷酸(NAD(P)H)氧化酶(Nox)的活性氧可能是糖尿病血管损伤的共同下游介质。目前的标准治疗包括优化血糖和血压,通常包括肾素-血管紧张素系统抑制剂。虽然这些干预措施能够延缓病情进展,但不能预防并发症的发生。因此,迫切需要确定糖尿病血管并发症的新靶点,这可能包括阻断 Nox 衍生的 ROS 形成,以及阻断 AGE 形成和 RAGE 激活抑制剂。这些策略可能会对糖尿病对血管的有害影响提供更好的保护。